Christopher Sveen - 28 Feb 2022 Form 4 Insider Report for HESKA CORP (HSKA)

Role
CAO & General Counsel
Signature
/s/ Catherine Grassman For: Christopher Sveen
Issuer symbol
HSKA
Transactions as of
28 Feb 2022
Transactions value $
-$3,310,920
Form type
4
Filing time
14 Jun 2023, 18:27:25 UTC
Previous filing
28 Sep 2021
Next filing
26 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HSKA Common Stock Award $0 +15,157 +1.79% $0 23,643 13 Jun 2023 Direct F1
transaction HSKA Common Stock Award $0 +3,948 +16.7% $0 27,591 13 Jun 2023 Direct F2
transaction HSKA Common Stock Disposed to Issuer -$3,310,920 -27,591 -100% $120 0 13 Jun 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HSKA Performance Shares Disposed to Issuer -750 -100% 0 13 Jun 2023 Common Stock 750 Direct F4, F5
transaction HSKA Non-Qualified Stock Option (right to buy) Award $0 +10,000 $0 10,000 28 Feb 2022 Common Stock 10,000 $60.94 Direct F6
transaction HSKA Non-Qualified Stock Option (right to buy) Award $0 +25,000 +2.5% $0 35,000 13 Jun 2023 Common Stock 25,000 $60.94 Direct F7
transaction HSKA Non-Qualified Stock Option (right to buy) Disposed to Issuer -35,000 -100% 0 13 Jun 2023 Common Stock 35,000 $60.94 Direct F6, F7, F8
transaction HSKA Incentive Stock Option (right to buy) Disposed to Issuer -2 -100% 0 13 Jun 2023 Common Stock 2 $60.94 Direct F8, F9
transaction HSKA Non-Qualified Stock Option (right to buy) Disposed to Issuer -9,998 -100% 0 13 Jun 2023 Common Stock 9,998 $60.94 Direct F8, F9
transaction HSKA Incentive Stock Option (right to buy) Disposed to Issuer -4,173 -100% 0 13 Jun 2023 Common Stock 4,173 $71.84 Direct F8, F10
transaction HSKA Non-Qualified Stock Option (right to buy) Disposed to Issuer -7,827 -100% 0 13 Jun 2023 Common Stock 7,827 $71.84 Direct F8, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Christopher Sveen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, these shares of performance-based restricted stock of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
F2 Pursuant to the Merger Agreement, these performance-based restricted stock units were fully accelerated assuming target level of performance immediately prior to the effectiveness of the merger.
F3 Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $120.00 per share of common stock of the Issuer (the "Merger Consideration") on the effective date of the merger.
F4 Pursuant to the Merger Agreement, these performance shares of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger and canceled in the merger in exchange for an amount in cash equal to $120.00 per share.
F5 1,500 performance shares previously vested and settled.
F6 Stock options of the Issuer became vested and exercisable upon achieving performance vesting conditions on February 28, 2022.
F7 Pursuant to the Merger Agreement, these stock options of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger.
F8 Stock options of the Issuer were canceled in the merger in exchange for an amount in cash equal to the difference, if any, between the Merger Consideration and the exercise price of such stock options.
F9 These stock options of the Issuer vested in two equal installments on December 31, 2021 and on December 31, 2022.
F10 These stock options of the Issuer vested in three equal installments on September 24, 2020, September 24, 2021 and September 24, 2022.